Novo Nordisk and Echosens partner up to develop diagnostics for "silent disease"

NASH, a metabolic liver disease, has no early stage symptoms, and people therefore go undiagnosed, which the two firms are now seeking to change.
Photo: Marcus Trappaud Bjørn/ERH
Photo: Marcus Trappaud Bjørn/ERH
by mikkel aabenhus hemmingsen, translated by daniel pedersen

NASH, or non-alcoholic steatohepatitis, is a focus area of Danish pharmaceutical giant Novo Nordisk – however, the disease’s nature poses a particular problem when it comes to treatment as it often goes undiagnosed until it is too late.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading